Meeder Advisory Services Inc. Has $826,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Meeder Advisory Services Inc. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 37.5% during the second quarter, Holdings Channel reports. The fund owned 7,281 shares of the medical device company’s stock after acquiring an additional 1,986 shares during the quarter. Meeder Advisory Services Inc.’s holdings in DexCom were worth $826,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom during the 2nd quarter valued at about $25,000. Sachetta LLC grew its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. DSM Capital Partners LLC acquired a new position in DexCom in the 4th quarter valued at approximately $28,000. Crewe Advisors LLC purchased a new stake in DexCom in the 1st quarter worth approximately $29,000. Finally, Riverview Trust Co acquired a new stake in shares of DexCom during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock valued at $201,708 over the last three months. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. UBS Group cut their price target on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Redburn Atlantic initiated coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Finally, Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $112.25.

DexCom Stock Up 1.0 %

Shares of DXCM stock opened at $69.51 on Friday. The stock has a 50 day moving average of $82.36 and a 200-day moving average of $111.25. The firm has a market cap of $27.85 billion, a PE ratio of 44.85, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm earned $0.34 EPS. The business’s revenue was up 15.3% on a year-over-year basis. On average, equities analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.